Company PledPharma AB (publ) Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Emcitate
97.3
%
| 16 | 40.9 % | 22 | 97.3 % | +39.92% |
PledOx
2.7
%
| 23 | 59.1 % | 1 | 2.7 % | -97.34% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Other Countries
19.9
%
| 6 | 15.0 % | 5 | 19.9 % | -21.49% |
France
17.3
%
| 3 | 7.6 % | 4 | 17.3 % | +33.52% |
Spain
15.0
%
| 3 | 7.6 % | 3 | 15.0 % | +17.48% |
United Kingdom
11.1
%
| 3 | 7.3 % | 3 | 11.1 % | -10.10% |
Italy
9.7
%
| - | - | 2 | 9.7 % | - |
Sweden
8.4
%
| 1 | 3.5 % | 2 | 8.4 % | +43.50% |
Australia
8.4
%
| - | - | 2 | 8.4 % | - |
Poland
7.5
%
| - | - | 2 | 7.5 % | - |
Japan
2.7
%
| 23 | 59.1 % | 1 | 2.7 % | -97.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 15/06/17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 30/12/17 |
Chief Tech/Sci/R&D Officer | - | 04/05/22 | |
Anna Sjögren
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
Chief Tech/Sci/R&D Officer | 56 | 28/02/23 | |
Henrik Krook
COO | Chief Operating Officer | 51 | 05/11/20 |
Director/Board Member | 50 | 31/12/19 | |
Karl Hård
IRC | Investor Relations Contact | 62 | 31/01/22 |
Nils Hallén
HRO | Human Resources Officer | 56 | 31/12/22 |
- | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 31/03/21 |
Director/Board Member | 50 | 31/12/19 | |
Thomas Lönngren
CHM | Chairman | 73 | 31/03/21 |
Director/Board Member | 63 | 31/12/16 | |
Director/Board Member | 63 | 31/12/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 292,571,459 | 212,443,237 ( 72.61 %) | 0 | 72.61 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |